Reliance Biosciences, also known as 睿信生醫, is at the forefront of molecular diagnostics, specializing in early Alzheimer's disease detection through protein markers found in exosomes present in blood. Exosomes are tiny particles secreted by specific cells linked to diseases, offering tailored and actionable insights into various conditions. Their cutting-edge immunoassay technology allows for highly sensitive detection of exosomal proteins in blood samples.

Currently, Reliance Biosciences is dedicated to the early detection of Alzheimer's disease, as it can be identified up to 15-20 years before symptoms manifest. With over a million Americans and people worldwide living with Alzheimer's, the need for accurate and timely diagnosis is crucial. The company is actively seeking partnerships with diagnostic labs for the development of laboratory-developed tests for early Alzheimer's diagnosis in Japan and the USA.

Technological milestones, including the successful execution of seed grants, licensing of proprietary technology from National Taiwan University, and the development of prototypes, demonstrate Reliance Biosciences' commitment to advancing diagnostic solutions. Their focus on collaboration and innovation positions them as a leader in the field of molecular diagnostics.